Trial · NCT06259175
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
NCT06259175, Completed, Servier Russia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH). Trials, record NCT06259175. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06259175
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- NCT number
- NCT06259175
- Status
- Completed
- Enrollment
- 396 participants, actual
- Lead sponsor
- Servier Russia
- Conditions
- Arterial Hypertension, HTN
- Interventions
- Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg, Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg, Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg
- First posted
- 2024-02-14
- Last updated
- 2025-06-11
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To describe antihypertensive effectiveness of the triple single-pill combination (SPC) of amlodipine, indapamide and perindopril in outpatients with arterial hypertension (HTN) who do not receive any other concomitant antihypertensive medicines within 12 | 12 weeks | Mean changes from baseline (BL) in SBP (systolic blood pressure) assessed at V3 (12+1 weeks after the SPC initiation). |
| Primary | To describe antihypertensive effectiveness of the triple single-pill combination (SPC) of amlodipine, indapamide and perindopril in outpatients with arterial hypertension (HTN) who do not receive any other concomitant antihypertensive medicines within 12 | 12 weeks | Mean changes from baseline (BL) in DBP (diastolic blood pressure) assessed at V3 (12+1 weeks after the SPC initiation). |
| Secondary | To describe changes in systolic blood pressure (SBP) from baseline to weeks 4 and 8 from the SPC initiation. | 4 weeks | Mean change from BL in SBP assessed at V1 (4+1 weeks after the SPC initiation) |
| Secondary | To describe changes in diastolic blood pressure (DBP) from baseline to weeks 4 and 8 from the SPC initiation. | 4 weeks | Mean change from BL in DBP assessed at V1 (4+1 weeks after the SPC initiation) |
| Secondary | To describe changes in systolic blood pressure (SBP) from baseline to weeks 4 and 8 from the SPC initiation. | 8 weeks | Mean change from BL in SBP assessed at V2 (8+1 weeks after the SPC initiation). |
| Secondary | To describe changes in diastolic blood pressure (DBP) from baseline to weeks 4 and 8 from the SPC initiation. | 8 weeks | Mean change from BL in SBP and DBP assessed at V2 (8+1 weeks after the SPC initiation). |
| Secondary | To describe a proportion of patients who reached SBP target goals at week 12 from the SPC initiation. | 12 weeks | Proportion of patients who reached SBP ≤130 mm Hg at V3 (12+1 weeks after the SPC initiation). |
| Secondary | To describe a proportion of patients who reached DBP target goals at week 12 from the SPC initiation. | 12 weeks | Prortion of patients who reached DBP \<80 mm Hg at V3 (12+1 weeks after the SPC initiation). |
| Secondary | To describe changes in patients' quality-of-life throughout the observational period of the study. | 12 weeks | Mean changes in scores of the Health-related quality of life Questionnaire for Patients with Hypertension (HRQoL) assessed at V3 (12+1 weeks after the SPC initiation). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06259175
GET https://conductscience.org/api/trials/v1/NCT06259175/registered